Physician profile
Michael B Melucci
NPI 1326048588
$3,402.03
in general payments reported to CMS, 2019-2025
23 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $52.17 · 2021: $371 · 2022: $429 · 2023: $1,007 · 2024: $831 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,346.70 | 2019-2025 | |
| Boston Scientific Corporation | $508.85 | 2019-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $304.64 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $270.33 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.43 | 2021-2025 | Jardiance |
| Pfizer INC. | $119.96 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $118.62 | 2022-2024 | Verquvo |
| Cvrx, INC. | $76.73 | 2021-2023 | Barostim Neo System |
| Atricure, INC. | $73.96 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $70.92 | 2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $60.19 | 2023-2025 | Onpattro |
| Esperion Therapeutics, INC. | $46.87 | 2021-2024 | Nexletol |
| Irhythm Technologies, INC. | $33.51 | 2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $32.89 | 2021-2022 | |
| Inspire Medical Systems, INC. | $22.42 | 2024 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $21.81 | 2019 | |
| Amgen INC. | $19.92 | 2023 | Repatha |
| Scpharmaceuticals INC. | $19.26 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $18.15 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $16.57 | 2021 | |
| Amarin Pharma, INC. | $15.62 | 2021 | |
| Cardiva Medical, INC. | $12.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Melucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.